1. Generics Bulletin
  2. >>Products

Reddy’s Gets Six-Month Head Start On Carboprost In US

 
• By Aidan Fry

Dr Reddy’s will be alone in the US market for six months with the first generic rival to Pfizer’s Hemabate carboprost brand.

Dartboard
Dr Reddy's is eligible for 180-day market exclusivity for the generic carboprost tromethamine vials it has just launched in the US • Source: Shutterstock

Dr Reddy’s Laboratories will benefit from six months of market exclusivity for the first generic rival to Pfizer’s Hemabate carboprost tromethamine single-dose vials that the Indian firm has introduced upon approval in the US.

By securing final approval from the Food and Drug Administration for the 250µg/1ml vials as a competitive generic therapy (CGT), Reddy’s has secured 180-day CGT market exclusivity. “We are pleased to be first-to-market with this product,” commented Marc Kikuchi, who became CEO of the group’s North America generics business earlier this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.